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Summary Rhizoxin is a macrocyclic lactone compound that binds to tubulin and inhibits microtubule
assembly. Rhizoxin demonstrated preclinical anti-tumour activity against a variety of human tumour cell lines
and xenograft models. Phase I evaluation found a maximum tolerated rhizoxin dose of 2.6 mg m 2, with
reversible, but dose-limiting, mucositis, leucopenia and diarrhoea. Clinical trials were then initiated by the
EORTC ECSG in melanoma, breast, head and neck, and non-small-cell lung cancers with the recommended
phase II rhizoxin dose of 2 mg m2. Pharmacological studies were instituted with the phase II trials to
complement the limited pharmacokinetic data available from the phase I trial. Blood samples were obtained
from 69 of 103 eligible patients enrolled in phase II rhizoxin studies, and these were evaluable for
pharmacokinetic analysis in 36 patients. Plasma rhizoxin concentrations were determined by high-performance
liquid chromatography (HPLC), and post-distribution pharmacokinetic parameters were estimated by a one-
compartment model. Rhizoxin was rapidly eliminated from plasma, with a median systemic clearance of
8.4 1 min-' m-2 and an elimination half-life of 10.4 min. Rhizoxin area under the concentration-time curve
(AUC) was higher in patients obtaining a partial response or stable disease than in those with progressive
disease (median 314 vs 222 ng ml-' min; P=0.03). As predicted from previous studies, haematological and
gastrointestinal toxicity was observed, but could not be shown to be related to rhizoxin AUC. This study
demonstrated the rapid and variable elimination of rhizoxin from the systemic circulation. The presence of
pharmacodynamic relationships and the low level of systemic toxicity suggest that future trials of rhizoxin with
alternative dosage or treatment schedules are warranted.
Keywords: rhizoxin; pharmacokinetics; pharmacodynamics; phase II trial
Rhizoxin is a 16-membered macrocyclic lactone that has
displayed cytotoxicity against a variety of human tumour cell
lines and activity in xenograft models (Hendriks et al., 1992).
The drug binds to tubulin at the vinblastine/maytansine site
and inhibits microtubule assembly, inducing a cell cycle block
at G2-M (Tsuruo et al., 1986; Sullivan et al., 1992). Preclinical
evaluation observed haematopoietic, gastrointestinal and
injection-site toxicity (Hendriks et al., 1992). A phase I trial
of rhizoxin administered as a 5 min infusion found a
maximum tolerated dose of 2.6 mg m-2 and a recommended
phase II dose of 2.0 mg m-2 (Bissett et al., 1992).
Myelosuppression was dose limiting, with grade 3-4
neutropenia in 7/8 patients receiving 2.6 mg m-2. An
objective response was observed in two patients with
advanced local recurrence of breast cancer, including the
patients with the highest area under the plasma concentra-
tion-time curve (AUC). Rhizoxin was only detectable in
plasma from patients receiving 2 mg m-2 in this study.
Pharmacodynamic analysis was not possible owing to the
small number of evaluable pharmacokinetic studies. The 4-
fold range of systemic clearance observed in the limited
number of patients studied provided further impetus for this
phase II pharmacokinetic/pharmacodynamic evaluation.
Materials and methods
Patients were accrued for pharmacological evaluation from
EORTC ECSG phase II trials of rhizoxin in melanoma,
breast, head and neck, and non-small-cell lung (NSCLC)
cancers (Kaplan et al., 1996; Verweij et al., 1996; Hanauske
et al., 1996). Participation in the pharmacological studies was
encouraged, but not mandatory in the phase II trials.
Rhizoxin 1.5-2.0 mg m-2 was administered intravenously
(i.v.) over 5 min (actual administration time 1-10 min).
Toxicity was graded by the NCI common toxicity criteria
after each course of therapy. The overall anti-tumour
response was evaluated for each patient after two courses
of therapy and graded as a complete response, partial
response, stable disease/no change or progressive disease.
The percentage change in absolute neutrophil count or white
blood cell count for each individual course was calculated as:
(pretreatment count-
lowest measured count/pretreatment count) * 100
Rhizoxin pharmacokinetic studies were performed with the
first administered dose. Blood samples (5 ml) were obtained
in heparinised tubes before therapy and 5, 10, 20 and 30 min
after infusion. The samples were then centrifuged (1000 g) for
5 min and plasma samples stored at -20°C until transport in
dry ice by express courier to the central drug analysis centre.
Samples were then maintained at -20°C until analysis.
As blood samples are processed with a varying degree of
urgency at individual institutions, the ex vivo degradation of
rhizoxin was assessed in the laboratory. Rhizoxin 50 ng ml-'
was added to aliquots of fresh human whole blood and
plasma and incubated at 26°C for 0, 0.5, 1, 2 and 3 h. Whole
blood samples were then centrifuged (1000 g) for 5 min and
plasma samples stored at -20°C until analysis.
Rhizoxin plasma concentrations were determined using a
previously described isocratic HPLC assay with ultraviolet
detection (Graham et al., 1992). Rhizoxin was extracted from
plasma by solid-phase extraction and separated on a C6
reverse-phase analytical column by HPLC with a mobile
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phase of 45% acetonitrile in 0.01 M phosphate buffer, pH 7,
at a flow rate of 1 ml min-'. Rhizoxin was detected as a
single peak (retention time 4 min) by ultraviolet detection at
310 nm. The interassay coefficient of variation at 10 ng ml-'
and 500 ng ml-' was <10%. The limit of detection was
1 ng ml-'.
A population pharmacokinetic model was initially
developed with data from the Glasgow phase I trial (Bissett
et al., 1992) and the current phase II population. The
computer package NONMEM was used to estimate mean
pharmacokinetic parameter values and their associated
standard deviation in the population (Boeckman et al.).
Estimates of the pharmacokinetic parameter values in the
individual patient were obtained using patient plasma
concentrations in a Bayesian algorithm (available in
NONMEM).
The intersubject variability of the pharmacokinetic
parameter values in the population was modelled using an
exponential structure, i.e. Pi= P exp (,), where P, represents
the parameter (clearance, volume, etc.) estimate of the ith
individual and P represents the typical value within the
population. rli represents the individual difference between Pi
and P and il is assumed to be normally distributed with
mean zero and variance w02.
The residual intrasubject variability was described using
an additive and proportional model: C1j= C,1/1 +Ei,,) + 82jp
where Cj represents the jth measured concentration in the
ith individual and Cij is the jth predicted concentration in
the ith individual. The differences in measured and
predicted concentrations are represented by 6lhj and e2ij,
which are assumed to be normally distributed with means
zero and variances al2 and a22 respectively. Pharmacody-
namic analysis was restricted to patients with evaluable
rhizoxin pharmacokinetics. Rhizoxin AUC was calculated
as: AUC =dose/systemic clearance. The median value of
rhizoxin AUC for each grade of toxic or therapeutic effect
was compared using the Kruskal-Wallis (K-W) test or the
Mann-Whitney (M-W) test as appropriate. Groups were
merged as indicated to provide sufficient numbers for valid
analysis.
Results
Blood sampling was performed in 69 of the 103 eligible
patients enrolled in the four phase II rhizoxin studies (67%)
(Kaplan et al., 1996; Verweij et al., 1996; Hanauske et al.,
1996). Of 18 centres involved in the phase II trials, 14
participated in the pharmacological evaluation of rhizoxin,
representing seven countries throughout Europe. Blood
sampling was performed in 78% of patients enrolled from
these 14 centres (range 11 - 100%). Accrual of plasma
samples varied by tumour type: NSCLC 24/29 (83%),
melanoma 19/26 (73%), head and neck 18/31 (58%), and
breast 8/17 (47%).
Rhizoxin was detectable in the plasma of 53 patients. The
remaining patients were not evaluable because of an
interfering plasma peak in the pretreatment sample (ten
patients), no detectable plasma rhizoxin (five patients) and no
early sampling secondary to acute toxicity (one patient).
Rhizoxin was detectable in the plasma of 70% of patients at
10 min after infusion, 25% of patients at 20 min after
infusion, and was detectable in only four patients at 30 min
after infusion.
The time between sample collection and processing was
unlikely to influence detection of rhizoxin, as little
degradation (<10% of rhizoxin was observed ex vivo in
human whole blood or plasma over 3 h.
Figure 1 shows that the rhizoxin plasma profile requires at
least a two-compartment model to describe the data. When
one- and two-compartment models were fitted to the data
using NONMEM, the two-compartment model gave a better
fit (x2=44 with 2 d.f., P<0.001). However, there were
insufficient data to estimate reliably the values for all four
parameters in the model (volume of distribution, elimination
constant and intracompartmental constants). The distribution
phase was very rapid and complete by 10 min after the end of
the infusion, so only the 5 min after infusion sample gave
information about distribution parameters. To overcome this
problem, all measured concentrations up to and including
5 min after the end of the infusion was censored and a one-
compartment model fitted to the remaining data from the
seven phase I and 36 phase II patients. The parameter values
and their associated errors estimated using this model are
given in Table I.
Individual parameter estimates derived using the Bayesian
algorithm implemented in NONMEM are summarised for all
36 phase II patients and for each tumour type in Table II. No
significant correlation was observed between patient age and
rhizoxin AUC.
The median AUC was not the same for all tumour types
(Table II; K-W, P=0.03). However, pairwise comparisons
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Figure 1 Concentration-time profile of rhizoxin in 37 phase II
patients with more than one detectable plasma sample.
Table I Population parameter estimates from a one-compartment
model NONMEM analysis
Standard error of
Estimate estimate
Clearance (1 min-' m-2) 7.6 0.93
co2 clearance (% CV) 0.375 (61%) 0.146
Volume of central 128.0 41.4
compartment (1 m-2)
co2 volume (% CV) 0.395 (63%) 0.293
a12 (% CV) 0.033 (18%) 0.0153
a22 (ng ml-1) 0.394 0.0347
Table II Median (and range) of individual parameter estimates for the 36 phase II patients and for each tumour type
Allpatients Breast (n =5) Head and neck (n =9) Melanoma (n = II) NSCLC (n = II)
Clearance (I min-' m-2) 8.4 (1.3-16.3) 8.8 (1.4-14.5) 10.8 (3.5-16.3) 9.9 (6.4-16.0) 6.4 (1.3-13.3)
Volume (1 m-2) 122 (27-156) 135 (28-156) 103 (85-146) 126 (81-135) 122 (27-139)
Half-life (min) 10.4 (3.5-19.2) 10.5 (6.6-18.2) 7.9 (3.6-19.2) 9.2 (3.5-14.7) 11.9 (6.8-17.2)
AUC (ng ml-1 min) 241 (115-1532) 230 (139-1422) 148 (115-414) 203 (124-314) 315 (150-1532),.....E
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of the median AUC in each tumour type failed to identify
significant differences when a Bonferroni correction was
applied to account for multiple testing.
As predicted from the preclinical and phase I studies,
toxicity from rhizoxin was primarily haematological (12%
patients with grade III, 16% with grade IV neutropenia),
gastrointestinal (5% patients with grade III stomatitis) and
alopecia (complete in 23% of patients). In addition, pain at
the tumour site was observed in five patients (Verweij et al.,
1996). No differences could be demonstrated in the median
AUC at different toxicity grades for any of the measures of
toxicity (Table III). No significant correlation could be
demonstrated between the percentage reduction in WBC or
the percentage in neutrophil count and rhizoxin AUC.
In the 36 patients evaluable for rhizoxin AUC, two
patients achieved a partial response (PR), seven had stable
disease (SD), and 23 had progressive disease (PD). Four
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patients were not evaluable in terms of tumour response. No
complete responses were observed among the patients with
evaluable rhizoxin pharmacokinetics. The nine cases with PR/
SD (six NSCLC, two head and neck and one melanoma) had
a significantly higher median AUC (314 ng ml-' min; range
138-1532) than the 23 patients with PD (222 ng ml-' min;
range 115 -1422) (Figure 2; M-W, P=0.03; 95% CI -16 to
-264). The small number of patients with PR/SD prohibited
separate statistical analysis for each tumour type.
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Figure 2 The relationship between rhizoxin AUC and tumour
response (Mann-Whitney test, P=0.03). SD, stable disease; PR,
partial response; PD, progressive disease. *Patients with very high
rhizoxin AUC values.
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Figure 3 Theoretical relationship between rhizoxin AUC and
measures of haematological toxicity (@, grade I/II; Dl, grade III/
IV) and tumour response (0). Symbols represent data from the
phase I (median 460ngml-1min) and phase II (median AUC
240 ngml- min) trials. The dashed lines for tumour response
represent two possible outcomes from further escalation of
systemic exposure: increased activity or plateau effect. There is
currently not enough clinical data available to validate the in vivo
presence of such relationships.
Table III Rhizoxin pharmacodynamics: comparison of median AUC and grade of toxicity
Toxicity n Median AUC Statistics
Alopecia Grade 0 7 252 ng ml-' min K-W, P=0.19
Grade 1 20 187
Grade 2 9 251
Asthenia Grade 0 25 252 ng ml- min M-W, P=0.94; 95% CI -64 to 102
Grade 1-3 11 222
Pain Grade 0 31 252 ng ml-' min Insufficient data
Grade 2-4 5 174
Skin Grade 0 28 251 ng ml-' min M-W, P=0.98; 95% CI -86 to 102
Grade 1-3 8 223
Stomatitis Grade 0 22 253 ng ml-' min M-W, P=0.88; 95% CI-58 to 102
Grade 1-3 14 223
WBC Grade 0 13 273 ng ml-' min K-W, P=0.18
Grade 1-2 14 204
Grade 3-4 9 224
Neutrophils Grade 0 16 252 ng ml min M-W, P=0.88; 95% CI -70 to 102
Grade 1-4 20 227
Platelets Grade 0 32 252 ng ml-1 min Insufficient data
Grade 1-2 4 223
Haemoglobin Grade 0 21 203 ng ml-' min M-W, P=0.68; 95% CI-103 to 55
Grade 1-3 15 274
M-W, Mann-Whitney test; K-W, Kruskal-Wallis test; CI, confidence interval for difference in median values.
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Discussion
Rhizoxin was rapidly eliminated from human plasma with a
median clearance of 8.4 1 min-' m-2 and elimination half-life
of 10.4 min. These results are consistent with those observed
in phase I pharmacokinetic analysis in which the median
clearance was 4.2 1 min-' m-2 and elimination half-life was
23.6 min. Rhizoxin was not detectable (<1 ng ml-') at
30 min after injection in 93% of plasma samples. A high
degree of interpatient variability in rhizoxin disposition was
observed in this study. Systemic clearance ranged from 1.3 to
16.3 1 min-' m-2 (CV=61%), while volume of distribution
was 27-156 1 m-2 (CV=63%). A similar degree of varia-
bility was observed in the phase I trial (clearance, 2.0-
4.6 1 min-' m-2; volume of distribution, 10.1-55.4
1 m-2)
(Bissett et al., 1992). In the current study, plasma rhizoxin
concentrations measured 5 min after infusion varied from
undetectable (<1 ng ml-') to 140 ng ml-' (median
10 ng ml-'). Two patients had plasma rhizoxin concentra-
tions (and AUC estimates) which are considerably higher
than in other patients (Figure 2). Both patients were from the
same centre, which raises questions as to the reason for the
high concentrations. However, they have been included in the
analysis. As pharmacokinetic studies were only performed
with the first course of rhizoxin, direct measurement of
intrapatient variability in rhizoxin pharmacokinetics was not
possible.
The rapid elimination of rhizoxin makes pharmacokinetic
analysis very difficult (McLeod et al., 1996). Traditional
methods of both compartmental and non-compartmental
pharmacokinetic analysis require 2-3 blood samples for each
variable to be estimated and data collection over at least
three half-lives to allow confident calculation of pharmaco-
kinetic parameters (Gibaldi and Perrier, 1982). Application of
these 'rules' in the current study would have used 8- 12 blood
samples over ) 30 min, beyond the point at which rhizoxin
was detectable in patient plasma. The difficulties in obtaining
accurate estimates of pharmacokinetic parameters for a two-
compartment model were such that only a one-compartment
model could be estimated. This required that early
concentration information be censored to give estimates of
post-distribution drug elimination.
Although unidentified species were not observed in the
chromatograms from patient plasma samples, the production
of metabolite(s) via rhizoxin metabolism may contribute to
the rapid elimination from plasma. The systemic clearance
was greater than liver blood flow (approximately 1.5 1 min-')
in all subjects, implying that extrahepatic metabolism or
degradation was involved. Another potential mechanism of
apparent clearance from plasma is binding to tubulin,
rhizoxin's molecular target (Sullivan et al., 1990). Several
blood and tissue components, including platelets, are rich in
tubulin (Wild et al., 1995). While binding to platelet tubulin
is a theoretical source of variability in rhizoxin disposition, ex
vivo incubation in whole blood or plasma for up to 3 h had
little influence on rhizoxin plasma concentrations.
Rhizoxin AUC was significantly higher in patients with
NSCLC (Table II). The mechanism for this alteration is not
clear. The patients in the NSCLC study did not have prior
systemic chemotherapy, ruling out the influence of platinum
complexes and related compounds on rhizoxin systemic
clearance. As a considerable degree of overlap in systemic
clearance was observed between the four tumour types, a
larger number of patients would need to be evaluated to
confirm that rhizoxin disposition is indeed different in
NSCLC patients.
Although a high level of variability in the systemic
exposure of rhizoxin was observed in this study, there was
no evidence that rhizoxin AUC was related to drug toxicity.
One contributing factor is the low degree of toxicity in this
study. Even among frequently occurring toxicities, the
majority of patients had grade I or II toxicity (Table III).
Indeed, 44% of patients had no neutropenia. Another
contributing factor is the absence of extensive measurement
of haematological parameters, needed for accurate determi-
nation of nadir values. The lowest measured value was used
to determine the % change in haematological parameters
induced by rhizoxin therapy, which may differ from the
actual nadir value. There is no easy solution to this
commonly encountered difficulty for pharmacodynamic
analysis, as daily analysis of the blood profile is not
practical. Bayesian modelling techniques for estimation of
individual patient neutrophil profile is in an early stage of
development and may provide a useful approach in the future
(Sonnichsen et al., 1994).
Rhizoxin plasma AUC was statistically higher in patients
achieving a PR or SD than those with progressive disease
(median 314 vs 222 ng ml-' min, P=0.03). However, the
response group contained nine patients, with the majority
having stabilisation of disease only. The percentage of
patients responding (PR+SD) was lower in those with
pharmacological analysis than the whole study population
(51% vs 28%) (Kaplan et al., 1996; Verweij et al., 1996;
Hanauske et al., 1996). Therefore, these results should be
viewed with caution until confirmed by a larger clinical trial.
Attention should also be paid to the choice of biological
matrix for evaluating the therapeutic effect of highly potent
drugs, such as rhizoxin. Variability in drug transport,
intracellular processing and interaction with the cellular
target are but a few of the influencing events between
measurement of a drug in plasma and pharmacological
activity. As measurement of drug concentrations or degree of
inhibition in microtubule assembly in the tumour is not
feasible for the majority of patients, use of an alternative
biological end point may be in order (Cassidy and McLeod,
1995). Methods for determination of paclitaxel action on
human platelet tubulin have been described following in vitro
incubations and may be applicable for guiding the use of
rhizoxin and other tubulin-interactive agents in future trials
(Rowinsky et al., 1988).
Another pharmacodynamic variable, which may be
important for rhizoxin, is the amount of time that drug
concentrations are maintained above a threshold concentra-
tion. This variable appears to be correlated with haemato-
logical toxicity in studies of other agents that interact with
tubulin, such as paclitaxel (Gianni et al., 1995; Huizing et
al., 1993). Relevant threshold concentrations are identified
using individual patient pharmacokinetic parameters to
simulate the concentration-time profile. In theory, this
represents in vivo evidence of saturable biological processes,
in which concentrations in excess of that required for
binding the cellular target do not contribute to the
pharmacological effect. Estimation of the time that rhizoxin
plasma levels were above specific values was not determined
in the current study, owing to the extensive assumptions in
rhizoxin pharmacokinetic profile that would have to be
made beyond 20 min after infusion. Future pharmacokinetic
analysis using more sensitive assay methodology (gas
chromatography with mass spectroscopy or enzyme-linked
inmmunosorbent assay) will be required to explore the
importance of threshold concentrations to rhizoxin toxicity
and therapeutic activity.
The absence of a significant relationship between toxicity
and rhizoxin systemic exposure in this study does not mean
that one does not exist. The majority of patients in the
pharmacological study (73%) had grade 0-II haematological
toxicity after 2 mg m-2, whereas only 7% of patients
obtained an objective response. In the phase I study of
rhizoxin, a dose of 2.6 mg m-2 led to grade III/IV
haematological toxicity in 87% of patients (Bissett et al.,
1992). These findings are consistent with the flat portion of
the exposure-tumour response curve (e.g. Figure 3), where a
relatively large increase in drug exposure does not translate
into greater drug effect on the tumour. They also suggest that
the in vivo concentration-effect curve for rhizoxin toxicity is
very steep. Indeed, assuming in vitro principles of pharmacol-
ogy hold true in humans, a concentration-effect curve, such
as the theoretical example shown in Figure 3, may explain the
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clinical profile of rhizoxin. It is not known whether an
increase in rhizoxin AUC will translate into greater anti-
tumour activity or if a plateau in response will occur.
Therefore, future trials using higher rhizoxin dosage, methods
for reducing dose-limiting side-effects, and/or alternative
dosage schedules should be considered.
In summary, rhizoxin is rapidly eliminated in humans,
with rhizoxin detectable in the plasma of only 7% of patients
by 30 min after injection. A large degree of interpatient
variability was observed for all pharmacokinetic parameters.
Rhizoxin plasma AUC was higher in patients achieving a
therapeutic response than in those with progressive disease.
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